4 completed, 1 not yet recruiting, 1 recruiting, 1 suspended. 9 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 4, Not yet recruiting 1, Recruiting 1, Suspended 1, Terminated 1, Unknown 1 |
| Phase 1 | 2 | Completed 1, Recruiting 1 |
| Phase 3 | 1 | Completed 1 |
Follow Inh: new trials by email Literature Review of Inh trials Research Report on Inh
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Daily Rifapentine Combined With Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age With and Without HIV Rifapentine, Isoniazid, Dolutegravir - Tuberculosis | Phase 1 / Phase 2 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 144 | 2026-09-28 | 2026-11-02 |
| Short-Course Regimen With Bedaquiline, Moxifloxacin and Pyrazinamide for Early Bactericidal Activity in Drug-Susceptible Tuberculosis Bedaquiline (B), Moxifloxacin, Pyrazinamide (PZA) - Tuberculosis, Pulmonary, Drug-Susceptible Pulmonary Tuberculosis | Phase 2 | Not yet recruiting | Shanghai Pulmonary Hospital, Shanghai, China | 45 | 2025-08-20 | 2025-08-19 |
| Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis Isoniazid, Rifampicin, Pyrazinamide - Pulmonary Tuberculosis | Phase 2 | Suspended | National Institute of Allergy and Infectious Diseases (NIAID) | 341 | 2025-03-11 | 2026-11-02 |
| Pharmacogenetics-guided Isoniazid Dosing in TB-HIV Isoniazid Tablets - Tuberculosis | Phase 2 | Unknown | Makerere University | 40 | 2021-12-07 | 2022-01-25 |
| Tuberculosis Clinical Trials Consortium Study 35 Rifapentine, Isoniazid - Latent Tuberculosis | Phase 1 / Phase 2 | Completed | Centers for Disease Control and Prevention | 69 | 2019-11-12 | 2026-07-24 |
| Infant TB Infection Prevention Study Isoniazid - Tuberculosis | Phase 2 | Completed | University of Washington | 300 | 2016-08-01 | 2023-04-28 |
| An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis Linezolid, Bedaquiline, Levofloxacin - Tuberculosis, Multidrug Resistant Tuberculosis | Phase 2 / Phase 3 | Completed | University of Cape Town | 154 | 2015-11-12 | 2021-09-29 |
| High-Dose Isoniazid Among Adult Patients With Different Genetic Variants of INH-Resistant Tuberculosis (TB) Isoniazid, Vitamin B6 - Tuberculosis | Phase 2 | Completed | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | 282 | 2014-08-13 | 2023-02-17 |
| Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV Standard-dose Lopinavir/Ritonavir, Double-dose Lopinavir/Ritonavir, Raltegravir - HIV Infection, Tuberculosis | Phase 2 | Terminated | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | 71 | 2013-07-13 | 2018-02-13 |
Tuberculosis (6) · Latent Tuberculosis (2) · Tuberculosis, Pulmonary (2) · Extensively Drug-Resistant Tuberculosis (1) · HIV Infections (1) · Tuberculosis, Multidrug-Resistant (1)
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Centers for Disease Control and Prevention (1) · Makerere University (1) · Shanghai Pulmonary Hospital, Shanghai, China (1) · University of Cape Town (1) · University of Washington (1)
South Africa (5) · Haiti (4) · Kenya (4) · Uganda (3) · Botswana (2) · Brazil (2) · Peru (2) · Thailand (2) · Zimbabwe (2) · India (1) · Malawi (1) · Mexico (1) · Philippines (1) · Vietnam (1)
Kelly Dooley, MD, PhD (2) · Andreas H Diacon, MD, PhD (1) · Anneke Hesseling, MD (1) · Avy Violari, MD (1) · Christine Sekaggya-Wiltshire, MBChB, PhD (1) · Constance A Benson, MD (1) · Grace John-Stewart, MD, PhD (1) · Keertan Dheda, MBChB (1) · Mark Cotton, MD (1) · Radojka Savic, PharmD, PhD (1) · Umesh Lalloo, MD, FRCP (1)
PMID 31932382, PMID 31945300, PMID 31969368, PMID 32564076, PMID 34403326, PMID 35175905, PMID 35315690, PMID 35607710, PMID 36808186, PMID 38564365, PMID 38768617, PMID 40195983, PMID 40817073, PMID 41504451
U01AI068636 (1), UM1AI068636 (1)